Skip to main content
. Author manuscript; available in PMC: 2020 Jun 27.
Published in final edited form as: J Med Chem. 2019 Jun 12;62(12):5810–5831. doi: 10.1021/acs.jmedchem.9b00136

Figure 7. Compounds 1, 8g and 21b suppress EBOV infection.

Figure 7.

Dose response of EBOV infection (blue) and cell viability (black) to compounds 1, 8g and 21b measured by plaque assay (for compound 1) or immunofluorescence assays (for compounds 8g and 21b) and CellTiter-Glo luminescent cell viability assay in Huh7 cells 48 hours after infection. Data are plotted relative to vehicle control. Shown are representative experiments from at least two conducted, each with 3 biological replicates; shown are means ± SD.